Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Glioma 1

Interventions

mirdametinib 3Imatinib Mesylate 3Surveys and Questionnaires 2tipifarnib 1talimogene laherparepvec 1pirfenidone 1nilotinib 1emvododstat 1diphenylcyclopropenone 1cabozantinib 1binimetinib 1Sunitinib 1Sirolimus 1Sevoflurane 1Propofol 1Percutaneous Collagen Induction 1Nitrous Oxide 1Magnetic Resonance Spectroscopy 1Lidocaine 1Lasers, Solid-State 1Lasers 1Glycopyrrolate 1Dexmedetomidine 1Blood Specimen Collection 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatoses × nilotinib × CNS × Clear all
NCT01275586 2017-04-12

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Indiana University

Phase EARLY_PHASE1 Completed
6 enrolled 7 charts
CNS

Neurofibroma, Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡